Friday, January 05, 2018 8:51:13 PM
POSTER #1651 IMAGE: http://www.peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf
"PS targeting decreases tumor-induced immunosuppression. Transferred antimelanoma CD4+ T cells migrate to tumors and promote tumor regression without off-target side effects.
• PS targeting is a desirable strategy that can improve the potency of anti-tumor strategies with known clinical off-target effects such as adoptive T cell transfer.
• PS targeting can be combined with CAR T cells to enhance anti-tumor potential. "
We attended Dr. Wolchok's recent lecture presentation in Baltimore last December at Johns Hopkins Adams Hall[~200 people in auditorium]. His topic was the current state of immuno-oncology therapy. We specifically wanted to hear what he might say in amplification of what he and I discussed at AACR 2017 in Washington, D.C. wrt the above poster. He did discuss the safety aspects of the CAR-T therapies of NVS, JUNO, and GILD/KITE, with the general observation that further work was necessary and ongoing to improve safety to mitigate unpredictable "cytokine storms."
In a Q&A after his lecture, I asked what MSKCC/Ludwig had done to implement the many posters of MSKCC/PPHM appearing at 2016 SITC, 2017 AACR and ASCO, and 2017 SITC wrt clinical trials in humans. I specifically mentioned the above poster. He replied[my paraphrase] "we have prepared a design for a clinical trial." In response to my next question about how that design would be carried out, Dr. Wolchok said "that depends on the company". Because of mutual time constraints, I did not have an opportunity to follow-up with questions to identify either 1)the trial indication or 2) the "company".
Bottom line: Recent events and PRs from PPHM[ongoing prior to 12/2017] evidence a marked change in focus of that company. Its former CEO and BOD are now gone, and a new BOD is in place with the announced intention of monetizing the PPHM assets by way of license or sale. The new company begins trading as CDMO 1/08/2018. Its next ASM is 1/18/2018.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137447228
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 11:07:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 09:08:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:45:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:43:35 PM
- Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial • Business Wire • 09/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:41:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:38:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:33:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:20:53 PM
- Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies • Business Wire • 09/10/2024 12:00:00 PM
- Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer • Business Wire • 09/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 07:23:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:18:35 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 08/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 06:23:44 PM
- Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA • Business Wire • 08/14/2024 05:59:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:22:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:06 PM
- Gilead Sciences Announces Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 08:02:00 PM
- U.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices Stall • IH Market News • 08/08/2024 09:55:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 09:28:51 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM